论文部分内容阅读
目的:探讨TGF-β1对胃癌细胞和多药耐药胃癌细胞增殖的影响及其机制。方法:采用MTT法、RT-PCR和酶联吸附反应检测24、48和72h的细胞生存抑制率、C-myc基因的表达和端粒酶活性。结果:在24、48和72h时TGF-β1处理的实验组SNU-601细胞生存抑制率分别为(18.66±1.37)%、(21.19±1.55)%和(31.51±1.71)%,SNU-601/cis10细胞生存抑制率分别为(38.90±2.56)%、(50.00±2.61)%和(50.38±1.86)%,各时间段与对照组相比,生存抑制率均显著增高,P值均为0.000;实验组多药耐药胃癌细胞生存抑制率与胃癌细胞相比明显增高,P均<0.05。RT-PCR测定结果,TGF-β1可时间依赖性抑制C-myc基因的表达和端粒酶活性,与对照组相比均明显降低,P均<0.05。端粒酶活性检测结果,TGF-β1时间依赖性抑制端粒酶活性,与对照组相比均明显降低,P均<0.05,对多药耐药胃癌细胞的端粒酶活性抑制作用更明显,在48和72h时端粒酶活性呈阴性,在各时间段与实验组胃癌细胞相比差异均有统计学意义,P均<0.05。结论:TGF-β1对SNU-601胃癌细胞及SNU-601/cis10多药耐药胃癌细胞具有抗增殖作用,并对多药耐药胃癌细胞的抑制作用更明显,其机制之一与抑制C-myc基因的表达及端粒酶活性有关。
Objective: To investigate the effect of TGF-β1 on the proliferation of gastric cancer cells and multidrug-resistant gastric cancer cells and its mechanism. Methods: MTT assay, RT-PCR and enzyme-linked immunosorbent assay were used to detect the cell viability, C-myc gene expression and telomerase activity at 24, 48 and 72 hours. Results: The survival inhibition rates of SNU-601 cells treated with TGF-β1 were (18.66 ± 1.37)%, (21.19 ± 1.55)% and (31.51 ± 1.71)%, respectively at 24, 48 and 72 h The survival inhibition rates of cis10 cells were (38.90 ± 2.56)%, (50.00 ± 2.61)% and (50.38 ± 1.86)%, respectively. Compared with the control group, the survival inhibition rates of cis10 cells were significantly increased (P = 0.000) The survival inhibition rate of multidrug-resistant gastric cancer cells in experimental group was significantly higher than that of gastric cancer cells (all P <0.05). The results of RT-PCR showed that TGF-β1 could inhibit the expression of C-myc gene and the activity of telomerase in a time-dependent manner, both of which were significantly lower than those of the control group (all P <0.05). The results of telomerase activity assay and time-dependent inhibition of telomerase activity of TGF-β1 were significantly lower than those of the control group (all P <0.05), which inhibited the telomerase activity of multidrug-resistant gastric cancer cells significantly, The telomerase activity was negative at 48 and 72 hours, and there were significant differences between the experimental group and the gastric cancer cells at each time point (P <0.05). CONCLUSION: TGF-β1 has antiproliferative effects on SNU-601 gastric cancer cells and SNU-601 / cis10 multidrug-resistant gastric cancer cells, and has more obvious inhibitory effect on multidrug-resistant gastric cancer cells. One of the mechanisms is that TGF- myc gene expression and telomerase activity.